In AD clinical trial, these tracers have demonstrated high binding affinity for tau PHFs and tau selectivity (Scholl et al., 2016; Shimada et al., 2017; Sone et al., 2017; Lu et al., 2020). Here, MAPT is linked to Alzheimer disease.